Drug screening on digital microfluidics for cancer precision medicine.

Autor: Zhai J; State Key Laboratory of Analog and Mixed-Signal VLSI, Institute of Microelectronics, University of Macau, Macau SAR, China.; Department of Biomedical Sciences, and Tung Biomedical Sciences Centre, City University of Hong Kong, Hong Kong SAR, China., Liu Y; State Key Laboratory of Analog and Mixed-Signal VLSI, Institute of Microelectronics, University of Macau, Macau SAR, China.; Faculty of Science and Technology, University of Macau, Macau SAR, China., Ji W; School of Computer and Communication Engineering, University of Science and Technology Beijing, Beijing, China., Huang X; Liver Transplantation Center, The Third Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China., Wang P; Department of Hepatobiliary Surgery, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China., Li Y; State Key Laboratory of Analog and Mixed-Signal VLSI, Institute of Microelectronics, University of Macau, Macau SAR, China., Li H; State Key Laboratory of Analog and Mixed-Signal VLSI, Institute of Microelectronics, University of Macau, Macau SAR, China.; Faculty of Science and Technology, University of Macau, Macau SAR, China., Wong AH; MoE Frontiers Science Center for Precision Oncology, University of Macau, Macau SAR, China., Zhou X; State Key Laboratory of Analog and Mixed-Signal VLSI, Institute of Microelectronics, University of Macau, Macau SAR, China.; College of electrical and information engineering, Hunan University, Changsha, China., Chen P; Cancer Center, Faculty of Health Sciences, University of Macau, Macau SAR, China., Wang L; College of electrical and information engineering, Hunan University, Changsha, China., Yang N; State Key Laboratory of Analog and Mixed-Signal VLSI, Institute of Microelectronics, University of Macau, Macau SAR, China.; Department of Electronic Information Engineering, Jiangsu University, Zhenjiang, China., Chen C; Liver Transplantation Center, The Third Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China., Chen H; Liver Transplantation Center, The Third Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China., Mak PI; State Key Laboratory of Analog and Mixed-Signal VLSI, Institute of Microelectronics, University of Macau, Macau SAR, China.; Faculty of Science and Technology, University of Macau, Macau SAR, China., Deng CX; Cancer Center, Faculty of Health Sciences, University of Macau, Macau SAR, China., Martins R; State Key Laboratory of Analog and Mixed-Signal VLSI, Institute of Microelectronics, University of Macau, Macau SAR, China.; Faculty of Science and Technology, University of Macau, Macau SAR, China.; On leave from Instituto Superior Tecnico, Universidade de Lisboa, Lisboa, Portugal., Yang M; Department of Biomedical Sciences, and Tung Biomedical Sciences Centre, City University of Hong Kong, Hong Kong SAR, China., Ho TY; Department of Compute Science and Engineering, The Chinese University of Hong Kong, Hong Kong, China., Yi S; Liver Transplantation Center, The Third Affiliated Hospital, Sun Yat-Sen University, Guangzhou, China. yishuhong@163.com., Yao H; School of Computer and Communication Engineering, University of Science and Technology Beijing, Beijing, China. hailongyao@ustb.edu.cn., Jia Y; State Key Laboratory of Analog and Mixed-Signal VLSI, Institute of Microelectronics, University of Macau, Macau SAR, China. yanweijia@um.edu.mo.; Faculty of Science and Technology, University of Macau, Macau SAR, China. yanweijia@um.edu.mo.; MoE Frontiers Science Center for Precision Oncology, University of Macau, Macau SAR, China. yanweijia@um.edu.mo.

Publikováno v: Nature communications [Nat Commun] 2024 May 22; Vol. 15 (1), pp. 4363. Date of Electronic Publication: 2024 May 22.

Novel pyridazinone derivatives bind to KSRP: Synthesis, anti-tumor biological evaluations and modelling insights.

Autor: Zhang J; Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China., Li S; Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China., Zheng Y; Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China., Gao L; Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China., Wei H; Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China., Li Y; Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China., Liu Y; Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. Electronic address: liuyonghua@imb.pumc.edu.cn., Zheng Y; Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. Electronic address: zhengyb@imb.pumc.edu.cn., Gong J; Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. Electronic address: ann_gong@imb.pumc.edu.cn.

Publikováno v: European journal of medicinal chemistry [Eur J Med Chem] 2024 Nov 15; Vol. 278, pp. 116811. Date of Electronic Publication: 2024 Aug 30.

Isoalantolactone/hydroxamic acid hybrids as potent dual STAT3/HDAC inhibitors and self-assembled nanoparticles for cancer therapy.

Autor: Mo H; School of Pharmacy and Food Engineering, Wuyi University, Jiangmen, 529020, China., Liu J; School of Pharmacy and Food Engineering, Wuyi University, Jiangmen, 529020, China., Su Z; School of Pharmacy and Food Engineering, Wuyi University, Jiangmen, 529020, China., Zhao DG; School of Pharmacy and Food Engineering, Wuyi University, Jiangmen, 529020, China. Electronic address: zhaodenggao@wyu.edu.cn., Ma YY; School of Pharmacy and Food Engineering, Wuyi University, Jiangmen, 529020, China. Electronic address: j002293@wyu.edu.cn., Zhang K; School of Pharmacy and Food Engineering, Wuyi University, Jiangmen, 529020, China., Wang Q; Department of Radiation Medicine, School of Public Health and Management, Wenzhou Medical University, Wenzhou, 325035, China., Fu C; Department of Radiation Medicine, School of Public Health and Management, Wenzhou Medical University, Wenzhou, 325035, China., Wang Y; School of Pharmacy and Food Engineering, Wuyi University, Jiangmen, 529020, China., Chen M; State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macau, 999078, China., Hu B; Department of Radiation Medicine, School of Public Health and Management, Wenzhou Medical University, Wenzhou, 325035, China. Electronic address: brhu@wmu.edu.cn.

Publikováno v: European journal of medicinal chemistry [Eur J Med Chem] 2024 Nov 05; Vol. 277, pp. 116765. Date of Electronic Publication: 2024 Aug 12.

Antitumor activities of anti‑CD44 monoclonal antibodies in mouse xenograft models of esophageal cancer.

Autor: Ishikawa K; Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, Aoba‑ku, Sendai, Miyagi 980‑8575, Japan., Suzuki H; Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, Aoba‑ku, Sendai, Miyagi 980‑8575, Japan., Ohishi T; Institute of Microbial Chemistry (BIKAKEN), Numazu, Microbial Chemistry Research Foundation, Numazu, Shizuoka 410‑0301, Japan., Nakamura T; Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, Aoba‑ku, Sendai, Miyagi 980‑8575, Japan., Yanaka M; Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, Aoba‑ku, Sendai, Miyagi 980‑8575, Japan., Li G; Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, Aoba‑ku, Sendai, Miyagi 980‑8575, Japan., Tanaka T; Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, Aoba‑ku, Sendai, Miyagi 980‑8575, Japan., Ohkoshi A; Department of Otolaryngology, Head and Neck Surgery, Tohoku University Graduate School of Medicine, Aoba‑ku, Sendai, Miyagi 980‑8575, Japan., Kawada M; Institute of Microbial Chemistry (BIKAKEN), Laboratory of Oncology, Microbial Chemistry Research Foundation, Shinagawa‑ku, Tokyo 141‑0021, Japan., Kaneko MK; Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, Aoba‑ku, Sendai, Miyagi 980‑8575, Japan., Katori Y; Department of Otolaryngology, Head and Neck Surgery, Tohoku University Graduate School of Medicine, Aoba‑ku, Sendai, Miyagi 980‑8575, Japan., Kato Y; Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, Aoba‑ku, Sendai, Miyagi 980‑8575, Japan.

Publikováno v: Oncology reports [Oncol Rep] 2024 Nov; Vol. 52 (5). Date of Electronic Publication: 2024 Sep 02.

Design, synthesis, and evaluation of antitumor activity of 2-arylmethoxy-4-(2-fluoromethyl-biphenyl-3-ylmethoxy) benzylamine derivatives as PD-1/PD-l1 inhibitors.

Autor: Zhang F; Lab of Chemical Biology and Molecular Drug Design, College of Pharmaceutical Science, Zhejiang University of Technology, Deqing, 313299, China; Institute of Drug Development & Chemical Biology, Zhejiang University of Technology, Deqing, 313299, China., Zhang H; Lab of Chemical Biology and Molecular Drug Design, College of Pharmaceutical Science, Zhejiang University of Technology, Deqing, 313299, China; Institute of Drug Development & Chemical Biology, Zhejiang University of Technology, Deqing, 313299, China; Department of Pharmacy, Changzhi Medical College, Shanxi, 046012, China., Zhou S; Lab of Chemical Biology and Molecular Drug Design, College of Pharmaceutical Science, Zhejiang University of Technology, Deqing, 313299, China; Institute of Drug Development & Chemical Biology, Zhejiang University of Technology, Deqing, 313299, China., Plewka J; Department of Organic Chemistry, Faculty of Chemistry, Jagiellonian University, Gronostajowa 2, 30-387 Krakow, Poland., Wang M; Lab of Chemical Biology and Molecular Drug Design, College of Pharmaceutical Science, Zhejiang University of Technology, Deqing, 313299, China; Institute of Drug Development & Chemical Biology, Zhejiang University of Technology, Deqing, 313299, China., Sun S; Lab of Chemical Biology and Molecular Drug Design, College of Pharmaceutical Science, Zhejiang University of Technology, Deqing, 313299, China; Institute of Drug Development & Chemical Biology, Zhejiang University of Technology, Deqing, 313299, China., Wu C; Lab of Chemical Biology and Molecular Drug Design, College of Pharmaceutical Science, Zhejiang University of Technology, Deqing, 313299, China; Institute of Drug Development & Chemical Biology, Zhejiang University of Technology, Deqing, 313299, China., Yu Q; Lab of Chemical Biology and Molecular Drug Design, College of Pharmaceutical Science, Zhejiang University of Technology, Deqing, 313299, China; Institute of Drug Development & Chemical Biology, Zhejiang University of Technology, Deqing, 313299, China., Zhu M; Lab of Chemical Biology and Molecular Drug Design, College of Pharmaceutical Science, Zhejiang University of Technology, Deqing, 313299, China; Institute of Drug Development & Chemical Biology, Zhejiang University of Technology, Deqing, 313299, China., Awadasseid A; Lab of Chemical Biology and Molecular Drug Design, College of Pharmaceutical Science, Zhejiang University of Technology, Deqing, 313299, China; Institute of Drug Development & Chemical Biology, Zhejiang University of Technology, Deqing, 313299, China; Moganshan Institute, Zhejiang University of Technology, Deqing, 313200, China. Electronic address: annoormohammed@zjut.edu.cn., Wu Y; Lab of Molecular Immunology, Virus Inspection Department, Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, 310051, China. Electronic address: ylwu@cdc.zj.cn., Magiera-Mularz K; Department of Organic Chemistry, Faculty of Chemistry, Jagiellonian University, Gronostajowa 2, 30-387 Krakow, Poland. Electronic address: k.magiera@uj.edu.pl., Zhang W; Lab of Chemical Biology and Molecular Drug Design, College of Pharmaceutical Science, Zhejiang University of Technology, Deqing, 313299, China; Institute of Drug Development & Chemical Biology, Zhejiang University of Technology, Deqing, 313299, China; Zhejiang Jieyuan Med-Tech Co., Ltd., Hangzhou, 311113, China. Electronic address: wzhang63@zjut.edu.cn.

Publikováno v: European journal of medicinal chemistry [Eur J Med Chem] 2024 Oct 05; Vol. 276, pp. 116683. Date of Electronic Publication: 2024 Jul 15.